Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | CPX-351 vs 7+3 in older high-risk AML patients

Thomas Prebet • 11 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia CPX-351 Cytarabine Daunorubicin

Thomas Prebet, MD, of the Yale School of Medicine, New Haven, CT, discusses the results of an exploratory analysis of the efficacy and safety of CPX-351 versus 7+3 in a Phase III study (NCT01696084) of older adults with high-risk/secondary acute myeloid leukemia (AML). Dr Prebet also highlights the importance of TP53 mutational status as a prognostic marker for success for patients in both treatment arms. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thomas Prebet

3:31
Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
Thomas Prebet • 18 Nov 2020
1:50
Hypomethylating agent based combinations in MDS
Thomas Prebet • 18 Nov 2020
2:19
AML: what to look forward to at ASH 2020
Thomas Prebet • 18 Nov 2020
1:19
New treatments for AML
Thomas Prebet • 7 Oct 2020

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals